We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Florham Park, NJ-based Zoetis Inc. (ZTS - Free Report) is one of the leading global animal health companies focused on the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The company came into existence following Pfizer’s decision to spin off its animal health business in 2013.
Zoetis’ diversified portfolio of products for livestock and companion animals should continue to drive top-line growth at the company. The company’s top line should benefit from the addition of products acquired from Abbott Laboratories (Feb 2015), Pharmaq (Nov 2015) as well as from the performance of Apoquel and other key brands. In this scenario, investor focus remains on top-and bottom-line numbers.
Zoetis’ track record has been impressive with the company beating earnings estimates consistently. In fact, Zoetis’ earnings surpassed expectations in each of the last four quarters, with an average positive surprise of 15.92%.
Currently, Zoetis has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Once again, Zoetis has surpassed earnings estimates. Zoetis beat on third-quarter 2016 earnings. The company reported EPS of 52 cents while our consensus called for EPS of 46 cents.
Revenues: Revenues in the reported quarter came marginally above expectations. Zoetis posted revenues of $1.24 billion above our consensus estimate of $1.22 billion.
2016 & 2017 Outlook Updated: Zoetis updated its outlook for 2016. The company now expects earnings in the range of $1.91 to $1.96 per share (old guidance: $1.86 to $1.93 per share) on revenues of $4.85 billion and $4.9 billion (old guidance: $4.8 billion and $4.9 billion). The Zacks Consensus Estimate for earnings is $1.89 per share on revenues of $4.9 billion.
The company also updated its outlook for 2017. In 2017, the company expects earnings in the range of $2.28 to $2.38 per share (old guidance: $2.24 to $2.38 per share) on revenues of $5.15 billion and $5.275 billion (old guidance: $5.075 billion and $5.275 billion). The Zacks Consensus Estimate for earnings is $2.34 per share on revenues of $5.23 billion.
Check back later for our full write up on this ZTS earnings report later!
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand.Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zoetis (ZTS) Beats Q3 Earnings Estimates, Updates '16 View
Florham Park, NJ-based Zoetis Inc. (ZTS - Free Report) is one of the leading global animal health companies focused on the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The company came into existence following Pfizer’s decision to spin off its animal health business in 2013.
Zoetis’ diversified portfolio of products for livestock and companion animals should continue to drive top-line growth at the company. The company’s top line should benefit from the addition of products acquired from Abbott Laboratories (Feb 2015), Pharmaq (Nov 2015) as well as from the performance of Apoquel and other key brands. In this scenario, investor focus remains on top-and bottom-line numbers.
Zoetis’ track record has been impressive with the company beating earnings estimates consistently. In fact, Zoetis’ earnings surpassed expectations in each of the last four quarters, with an average positive surprise of 15.92%.
ZOETIS INC Price and EPS Surprise
ZOETIS INC Price and EPS Surprise | ZOETIS INC Quote
Currently, Zoetis has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Once again, Zoetis has surpassed earnings estimates. Zoetis beat on third-quarter 2016 earnings. The company reported EPS of 52 cents while our consensus called for EPS of 46 cents.
Revenues: Revenues in the reported quarter came marginally above expectations. Zoetis posted revenues of $1.24 billion above our consensus estimate of $1.22 billion.
2016 & 2017 Outlook Updated: Zoetis updated its outlook for 2016. The company now expects earnings in the range of $1.91 to $1.96 per share (old guidance: $1.86 to $1.93 per share) on revenues of $4.85 billion and $4.9 billion (old guidance: $4.8 billion and $4.9 billion). The Zacks Consensus Estimate for earnings is $1.89 per share on revenues of $4.9 billion.
The company also updated its outlook for 2017. In 2017, the company expects earnings in the range of $2.28 to $2.38 per share (old guidance: $2.24 to $2.38 per share) on revenues of $5.15 billion and $5.275 billion (old guidance: $5.075 billion and $5.275 billion). The Zacks Consensus Estimate for earnings is $2.34 per share on revenues of $5.23 billion.
Check back later for our full write up on this ZTS earnings report later!
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>